article thumbnail

Get Your Story Straight: Patent Office Cracks Down on Inconsistent Statements Made Before the FDA

Bill of Health

In the July 29, 2022 notice, the USPTO set forth its views on the “duty of disclosure” and “duty of reasonable inquiry,” emphasizing the importance of consistency between statements made to the USPTO, the FDA, and other governmental agencies. MPEP § 2016. Background Context. The Duty of Reasonable Inquiry.

FDA 130
article thumbnail

Cell Therapies and their Legal Discontents

Bill of Health

In February, the news broke that the Food and Drug Administration (FDA) had approved a “first of its kind” new cancer therapy. Exciting as this is, cell therapies face complex regulatory schemes and various levers to the process of FDA approval. government and a private stem cell clinic in California. The procedures in question?

FDA 111
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA Oversight of AI Software Developed by Health Care Providers

Health Law Advisor

But the question is, to what extent do health care providers need to worry about FDA requirements as they use AI? FDA has been regulating machine learning algorithms used in a clinical context for decades. It’s important to understand that FDA regulation isn’t punitive in the sense that it’s only intended to apply to bad people.

FDA 98
article thumbnail

Anti-Abortion Advocacy Groups’ Challenge to FDA-Approved Abortion Pill May Have Far-Reaching Consequences

Health Law Advisor

Food and Drug Administration (“FDA”) to withdraw approval of Mifepristone, an FDA-approved drug used to end pregnancies in the first trimester. [1] The lawsuit has sparked concern by both industry and the FDA. Twenty years later, Congress codified the pathway in the FDA Safety and Innovation Act (“FDASIA”) [4].

FDA 59
article thumbnail

How Soon Could President Biden Enable Generic Competition to Xtandi? Very Quickly, If There Is the Will.

Bill of Health

government had funded the R&D for each of the three patented inventions that are currently blocking generic competition. government has a “paid-up license to practice or have practiced for or on behalf of the United States” the invention “throughout the world” ( 35 U.S.C. As a consequence of this funding, the U.S.

Licensing 261
article thumbnail

The Legal Battle Over Mifepristone

Health Law Advisor

FDA have called into question the U.S. Food and Drug Administration’s (“FDA’s”) scientific review process to approve new drug applications. The Texas District Court ruling had the effect of suspending the FDA’s approval of mifepristone. During the past several turbulent weeks for the U.S. While the U.S.

FDA 97
article thumbnail

Access to Abortion Pill in Limbo: Navigating the Intricacies of Conflicting Federal Court Rulings in Texas and Washington State

Healthcare Law Blog

Food and Drug Administration’s (“FDA”) approval of the commonly-used abortion medication, Mifepristone, has been curtailed following dueling federal court decisions in Texas and Washington. Just days after a Texas federal judge’s ruling suspended the FDA’s approval of the drug, the U.S. Fifth Circuit Order, at 2.

FDA 52